Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology

被引：10
|
作者：
Kaimakliotis, Hristos Z. [1 ]
Monn, M. Francesca [1 ]
Cho, Jane S. [1 ]
Pedrosa, Jose A. [1 ]
Hahn, Noah M. [2 ]
Albany, Costantine [3 ]
Gellhaus, Paul T. [1 ]
Cary, K. Clint [1 ]
Masterson, Timothy A. [1 ]
Foster, Richard S. [1 ]
Bihrle, Richard [1 ]
Cheng, Liang [3 ]
Koch, Michael O. [1 ]
机构：
[1] Indiana Univ Sch Med, Dept Urol, 535 Barnhill Dr, Indianapolis, IN 46202 USA
[2] Johns Hopkins Sch Med, Dept Genitourinary Med Oncol, 1550 Orleans St,Room 1M51, Baltimore, MD 21287 USA
[3] Indiana Univ Sch Med, Dept Genitourinary Med Oncol, 535 Barnhill Dr, Indianapolis, IN 46202 USA
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 15期
关键词：
GEMCITABINE PLUS CISPLATIN; RADICAL CYSTECTOMY; POOR-PROGNOSIS; PHASE-III; CARCINOMA; METHOTREXATE; VINBLASTINE; DOXORUBICIN; SURVIVAL; METAANALYSIS;
D O I：
10.2217/fon-2016-0056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.
引用
收藏
页码：1795 / 1804
页数：10
相关论文
共 50 条
  • [31] ELIGIBILITY OF PATIENTS WITH UROTHELIAL CANCER OF THE BLADDER FOR NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
    Vemana, Goutham
    Sandhu, Gurdarshan
    Nepple, Kenneth
    Strope, Seth
    JOURNAL OF UROLOGY, 2013, 189 (04): : E54 - E54
  • [32] NEOADJUVANT CHEMOTHERAPY FOR UROTHELIAL BLADDER CANCER: TUMOR REGRESSION IS AN INDEPENDENT PREDICTOR OF SURVIVAL
    Seiler, Roland
    Fleischmann, Achim
    Perren, Aurel
    Thalmann, George N.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E769 - E769
  • [33] SYSTEMIC CHEMOTHERAPY REGIMEN FOR BLADDER CANCER INFLUENCES OUTCOME IN NEOADJUVANT AND ADJUVANT SETTINGS
    Wosnitzer, Matthew
    Hruby, Greg
    Barlow, Lamont
    Cordon-Cardo, Carlos
    Benson, Mitchell
    Petrylak, Daniel
    McKiernan, James
    JOURNAL OF UROLOGY, 2010, 183 (04): : E656 - E657
  • [34] Radical cystectomy for bladder urothelial carcinoma with aggressive variant histology
    Mehrnoush, Vahid
    Brennan, Logan
    Ismail, Asmaa
    Zakaria, Ahmed
    Elmansy, Hazem
    Shahrour, Walid
    Prowse, Owen
    Kotb, Ahmed
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2022, 94 (03) : 291 - 294
  • [35] Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy
    Campbell, Rebecca A.
    Khanna, Abhinav
    Boorjian, Stephen A.
    Knorr, Jacob
    Cox, Roni
    Nicholas, Marlo
    Cheville, John
    Sharma, Vidit
    Murthy, Prithvi B.
    Tarrell, Robert
    Thapa, Prabin
    Tollefson, Matthew K.
    Thompson, R. Houston
    Frank, Igor
    Karnes, R. J.
    Haber, Georges Pascal
    Lee, Byron
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 157 - 163.e1
  • [36] IMPACT OF NEOADJUVANT CHEMOTHERAPY ON PATHOLOGIC DOWNSTAGING IN PATIENTS WITH VARIANT HISTOLOGY UNDERGOING RADICAL CYSTECTOMY
    Campbell, Rebecca
    Khanna, Abhinav
    Boorjian, Stephen
    Knorr, Jacob
    Cox, Roni
    Nicholas, Marlo
    Sharma, Vidit
    Murthy, Prithvi
    Tarrell, Robert
    Thapa, Prabin
    Tollefson, Matthew
    Thompson, R. Houston
    Frank, Igor
    Karnes, R. Jeffrey
    Haber, Georges-Pascal
    Lee, Byron
    JOURNAL OF UROLOGY, 2021, 206 : E906 - E906
  • [37] Variant Histology: The Impact on Oncological Outcomes of Patients with Urothelial Carcinoma of The Bladder Treated with Radical Cystectomy
    Hazir, Berk
    Haberal, Hakan Bahadir
    Baltaci, Kadir Emre
    Shahsuvarli, Parviz
    Akdogan, Bulent
    Bilen, Cenk Yucel
    Yazici, Mustafa Sertac
    JOURNAL OF UROLOGICAL SURGERY, 2021, 8 (04): : 243 - 247
  • [38] The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy
    Li, Qiang
    Assel, Melissa
    Benfante, Nicole E.
    Pietzak, Eugene J.
    Herr, Harry W.
    Donat, Machele
    Cha, Eugene K.
    Donahue, Timothy F.
    Bochner, Bernard H.
    Dalbagni, Guido
    EUROPEAN UROLOGY FOCUS, 2019, 5 (01): : 104 - 108
  • [39] THE IMPACT OF PLASMACYTOID VARIANT HISTOLOGY ON SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER AFTER RADICAL CYSTECTOMY
    Li, Qiang
    Assel, Melissa
    Pietzak, Eugene
    Sjoberg, Daniel
    Herr, Harry
    Donat, Machele
    Cha, Eugene
    Bochner, Bernard
    Dalbagni, Guido
    JOURNAL OF UROLOGY, 2017, 197 (04): : E255 - E255
  • [40] NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER
    Meijer, R. P.
    Nieuwenhuijzen, J. A.
    Meinhardt, W. A.
    Bex, A.
    Van Der Poel, H. G.
    Van Rhijn, B. W.
    Kerst, J. M.
    Bergman, A. M.
    Van Tinteren, H.
    Horenblas, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 208 - 209
12345